Genmab — April 2020

[lahn1]

Der kommer mere - Gilead also said that a government-run clinical trial evaluating remdesivir in severely ill COVID-19 patients met the study's primary endpoint. That study is being conducted by the National Institute of Allergy and Infectious Diseases, which is expected to provide additional information about that trial end of May.

[kkjoel]

Hvis det kan hjælpe pts og hospitaler er det fint.. men det er der sikkert mange andre ting der kan

[kkjoel]

Ja, lahn, lad os nu se....

[Solsen]

Man mener at have noget fornuftigt og afslutter med at sige vi høres ved sidst i maj ???

[Solsen]

Jeg kunne godt forestille mig, at plasma har helbredt mange og er kørt godt ind inden. Vi er måske heldige med en effekt på 60-80%

[Bulder]

Solsen, du skal skelne mellem NIAID-studiet og Gileads egne 2 studier, hvor vi vil få resultarer sidst i maj. Det andet Gilead-studie (moderat): "shortly". Niaid: "upcoming)

[Bulder]

Rettelse: Moderat: sidst i maj. Svær covid19 "shortly"

[Bulder]

I øvrigt ville det være bedst, hvis vi fører covid19 diskussion i covid19-chatten, når nu Helge har gjort sig den ulejlighed at oprette den.

[Solsen]

Ok

[Helge_LarsenPI-redaktør]

Tak Bulder.

[E_L]

i think i might have the one to blame lol

[E_L]

Upregulation of CD38 expression on multiple myeloma cells by novel HDAC6 inhibitors is a class effect and augments the efficacy of daratumumab https://www.nature.com/articles/s41375-020-0840-y

[Sukkeralf]

We already have seen Farydak (panobinostat) - a pan HDAC inihibitor approved for MM. I dont think Novartis ever made trials with daratumumab even though panobinostat also upregulates CD38. Tox issues with HDAC are heavy if I remember correctly

[E_L]

do you happen to know if JNJ owns such an inhibitor?

[Sukkeralf]

but maybe its a different story with a selective HDAC6 inhibitor - so lets give ricolinostat a warm welcome in combination with daratumumab :-)'

[Sukkeralf]

I dont think so

[E_L]

[Sukkeralf]

Its seems like Celgene bought Acetylon Pharmaceuticals and outsourced ricolinostat to Regenacy Pharmaceuticals

[Sukkeralf]

So I guess we will not see anything from that - nice papers but no commercial value

[GeorgeBest]

Webinar https://twitter.com/genmab/status/1255519832063258624?s=21